Ludwig In the News

December 8, 2022
The New England Journal of Medicine

Ludwig Lausanne’s George Coukos wrote an editorial highlighting the results of a phase 3 clinical trial which showed that a treatment that uses immune cells harvested from a patient’s own tumors to treat melanoma was more effective as a second line therapy than the leading alternative treatment.

November 28, 2022
Agência FAPESP

This interview with Ludwig Institute Scientific Director Chi Van Dang, written in Portuguese, covers his work on cancer cell metabolism and chronobiology and his views on matters ranging from the future of cancer therapy to the challenges of developing cancer drugs.

November 28, 2022
News Medical

Researchers led by Ludwig Chicago’s Sean Pitroda report that local tumor irradiation alone does not positively stimulate anti-tumor immune responses in patients with metastatic non-small cell lung cancer. The researchers also found that the addition of immunotherapy to radiotherapy (RT) reverses the radiation-induced suppression of the immune response, culminating in more effective tumor cell clearing than RT alone.

November 14, 2022
The Hub at Johns Hopkins

This feature on Chi Van Dang, scientific director of the Ludwig Institute for Cancer Research, reports on his contributions to cancer research and his return to Johns Hopkins University, where he completed his medical training and residency and began his career as an academic researcher, serving on the faculty for more than two decades.


October 28, 2022
Genetic Engineering & Biotechnology News

This article reports on a new nanoparticle developed by researches led by Chicago’s Ralph Weichselbaum, Wenbin Lin and Kaiting Yang that accumulates in tumors and triggers potent therapeutic immune responses in mouse models of multiple cancers.

September 29, 2022
Princeton Alumni Weekly

This article reports on the establishment of the Princeton Branch of the Ludwig Institute for Cancer Research. It discusses the major research goals of the Branch and the importance of studying the role and influence of metabolism in cancer growth and therapy.

September 1, 2022

Ludwig San Diego postdoctoral researcher Beata Mierzwa has co-created a new cell biology video game, named Microscopya, to encourage girls to pursue careers in science and technology-related fields.


August 25, 2022
TBR NewsMedia

This second installment of a two-part series featuring the reminiscences of Cold Spring Harbor Laboratory alumni includes Ludwig Princeton’s Eileen White, who recalls her time there as a postdoctoral fellow in Bruce Stillman’s laboratory.

August 10, 2022
The ASCO Post

Ludwig Cancer Research recently announced the appointment of Pat Morin as deputy scientific director of the Ludwig Institute for Cancer Research.

June 20, 2022
Oncology Times

In an interview with Oncology Times, Ludwig Princeton Director Joshua Rabinowitz discussed the findings of a study he published in the journal Med showing that a ketogenic diet with chemotherapy tripled survival time compared with chemotherapy alone in mouse models of pancreatic ductal adenocarcinoma.

June 16, 2022
New Jersey Business Magazine

Ludwig Princeton Associate Director Eileen White has been selected as a team leader for a $25 million Cancer Grand Challenges award to tackle cachexia, a debilitating wasting condition associated with advanced cancers that worsens patient prognosis and quality of life.

June 4, 2022

Researchers co-led by Ludwig Johns Hopkins scientists, their colleagues at Johns Hopkins University and Ludwig alumni at WEHI, in Melbourne, Australia reported at the 2022 ASCO Annual Meeting that circulating tumor DNA (ctDNA) — genetic material shed from tumors into the bloodstream — can identify stage II colon cancer patients who can most benefit from chemotherapy following surgery and spare other patients the need for this form of treatment.

May 26, 2022
Nature Asia

Ludwig Harvard’s Kai Wucherpfennig published a study in Nature reporting the design and preclinical evaluation in mice and primates of a new type of cancer vaccine that could be of nearly universal utility to cancer patients.

May 5, 2022

In this radio interview, Alexandra Richard of CQFD speaks with Lana Kandalaft (in French) about clinical trials at Ludwig Lausanne evaluating individualized dendritic cell vaccines for the treatment of lung, pancreatic and, soon, ovarian cancers.

April 10, 2022
USA Today*

This article covers the story and promising findings of an ongoing clinical trial led by Ludwig Stanford’s Michelle Monje and Crystal Mackall of a novel immunotherapy for universally lethal H3K27M-mutated diffuse midline gliomas.

March 20, 2022
Johns Hopkins Magazine – Spring 2022

This profile of Bert Vogelstein and Ken Kinzler, co-directors of Ludwig Johns Hopkins, tells the story of their long partnership and outsize contributions to cancer genomics and its application to cutting edge diagnostics and therapies.

March 1, 2022
Krebsforschung Schweiz

In this brief interview (in French), Ludwig Lausanne’s Johanna Joyce discusses her research on glioblastoma, her laboratory’s current focus in that area and what most motivates her in her work.

February 28, 2022
Heidi News*

This article, which is in French, reports on cancer vaccine trials underway involving Ludwig Lausanne researchers Lana Kandalaft, Michal Bassani-Sternberg and Alexandre Harari.

February 15, 2022
Daily Guardian

This study, led by Ludwig Princeton Branch Director Joshua Rabinowitz, shows that a ketogenic diet synergizes with chemotherapy to triple survival time compared to chemotherapy alone in rigorous mouse models of pancreatic ductal adenocarcinoma (PDAC).

January 24, 2022

A team of researchers led by Ludwig Stanford’s Michelle Monje discovered that the brain fog associated with long-COVID shares many features with cancer therapy-related cognitive impairment (CRCI).

January 22, 2022
Thanh Nien

In this interview, which is in Vietnamese, Ludwig Scientific Director Chi Van Dang discusses his family, what drew him to medicine and cancer research and the state of cancer care in the U.S. and Vietnam. Dang also shares his current efforts and plans to support biomedical research and medical training in Vietnam.

January 18, 2022

Cancer Research UK, Vaccitech and Ludwig Cancer Research announced the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The trial follows promising preclinical research in mouse models by Benoit Van den Eynde’s group at Ludwig Oxford.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?